[Pharmacokinetics and clinical evaluation of amoxicillin sustained release preparation].
C-AMOX--long acting amoxicillin preparation (gastro coating 3, enterocoating 7)--has been investigated to give following results. A pharmacokinetic study of C-AMOX was conducted in 6 healthy male volunteers in postprandial state (30 minutes after light mean). The levels of 1.8--2.5 micrograms/ml in blood was detected for 6 hours after 500 mg dose orally. It was seemed to be long acting amoxicillin in blood levels. And, the calculated data of AUC of C-AMOX was 15.17 micrograms . hr/ml administered 500 mg dose, and 14.33 micrograms . hr/ml of AMPC twice 250 mg doses, respectively. The urinary excretion rate was 56.1% of the dose during 10 hours. Sixty-six patients with respiratory tract infections, urinary tract infections and others were treated with C-AMOX 0.5 g twice daily for 4--7 days mainly. Thirty one patients of all were cured excellent, 27 were good, 4 were fair and 4 were poor. The global efficacy rate was 87.9%. Only 1 patient was occurred diarrhea, and no abnormal laboratory finding was observed.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000658:Amoxicillin / Q000008:administration & dosage / Q000009:adverse effects / Q000378:metabolism*; D003692:Delayed-Action Preparations; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007700:Kinetics; D008297:Male; D008875:Middle Aged; D012141:Respiratory Tract Infections / Q000188:drug therapy*; D014552:Urinary Tract Infections / Q000188:drug therapy*
D003692:Delayed-Action Preparations; D000658:Amoxicillin